^
    1d
    A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients (clinicaltrials.gov)
    P2, N=160, Recruiting, Chinese PLA General Hospital | Active, not recruiting --> Recruiting
    Enrollment open
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • Epidaza (chidamide) • aclarubicin
    1d
    WT1 mRNA in peripheral blood enables early prognostic stratification in AML patients receiving venetoclax and azacitidine therapy. (PubMed, Ann Hematol)
    Moreover, achieving PB WT1 mRNA negativity-regardless of whether this occurred early or later in the therapy།was consistently associated with superior OS and PFS. These findings suggest that PB WT1 mRNA is a sensitive and reliable biomarker for predicting treatment response and long-term outcomes in patients with AML receiving VEN/AZA.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • WT1 (WT1 Transcription Factor)
    |
    Venclexta (venetoclax) • azacitidine
    1d
    Leukemic stem cell subtypes determine venetoclax resistance and therapeutic vulnerabilities in AML. (PubMed, Cell Stem Cell)
    LSC subtyping improves genetic risk stratification and provides subtype-specific therapies: venetoclax-resistant MEP-LSCs respond to BCL-xL inhibitors, whereas MoDe-LSCs are sensitive to MEK1/2 inhibition. Our findings reveal four distinct LSC types with unique vulnerabilities and propose biomarker-guided treatment strategies that complement genetic profiling to overcome venetoclax resistance.
    Journal • IO biomarker
    |
    BCL2L1 (BCL2-like 1)
    |
    Venclexta (venetoclax) • azacitidine
    2d
    Salvage Haploidentical HSCT With DLI and Targeted Therapy for R/R AML (clinicaltrials.gov)
    P=N/A, N=40, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    New trial
    |
    Venclexta (venetoclax) • sorafenib • azacitidine • cyclophosphamide • fludarabine IV
    2d
    A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=0, Withdrawn, M.D. Anderson Cancer Center | N=24 --> 0 | Trial completion date: Jun 2032 --> Apr 2026 | Initiation date: Aug 2026 --> Apr 2026 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jun 2030 --> Apr 2026
    Enrollment change • Trial completion date • Trial initiation date • Trial withdrawal • Trial primary completion date
    |
    clonoSEQ
    |
    cytarabine • pelcitoclax (APG-1252) • lisaftoclax (APG-2575) • fludarabine IV
    3d
    Verona: Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome (clinicaltrials.gov)
    P3, N=531, Active, not recruiting, AbbVie | Trial completion date: Mar 2026 --> Jul 2027 | Trial primary completion date: Mar 2026 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • azacitidine
    3d
    Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis (clinicaltrials.gov)
    P1, N=24, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Chr t(11;14)
    |
    Venclexta (venetoclax) • Ninlaro (ixazomib) • Hemady (dexamethasone tablets)
    3d
    VENP-A-QUI: A study to compare Venetoclax Azacitidine and Quizartinib Vs Venetoclax and Azacitidine in newly diagnosed acute myeloid leukemia patients ineligible for standard induction chemotherapy (2025-522979-29-00)
    P2/3, N=350, Recruiting, Fundacion PETHEMA | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Venclexta (venetoclax) • azacitidine • Vanflyta (quizartinib)
    3d
    NCI-2021-01791: Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, OHSU Knight Cancer Institute | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2026 --> Dec 2027 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    Venclexta (venetoclax) • dasatinib • Rituxan (rituximab) • Blincyto (blinatumomab) • methotrexate • Truxima (rituximab-abbs)
    4d
    Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy. (PubMed, Cancer)
    Collectively, these findings suggest that ASXL1MUT AML may be more appropriately classified as intermediate risk in the context of LIT+VEN-based therapy, with the depth of impact influenced by the specific LIT backbone.
    Retrospective data • Journal
    |
    TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • ASXL1 (ASXL Transcriptional Regulator 1)
    |
    TP53 mutation • FLT3-ITD mutation • RAS mutation • ASXL1 mutation
    |
    Venclexta (venetoclax) • cytarabine • cladribine
    4d
    Cardiovascular Adverse Events During Venetoclax-Based Treatment in Acute Myeloid Leukemia. (PubMed, J Am Heart Assoc)
    In conclusion, MACE is a clinically significant event that occurs in 6.5% of patients with AML treated with venetoclax and is a higher-risk event for patients with secondary AML or treatment-related AML.
    Journal • Adverse events
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax)